Best in Biotech 17 Mar 2023
67% five-year survival rate in glioblastoma therapy, according to CANbridge Pharmaceuticals study
CANbridge Pharmaceuticals Inc. has announced that its therapy for glioblastoma has shown a 67% survival rate at five years, three…